海通国际发布荣昌生物研报 公司跟踪报告:销售稳步增长 研发有序推进

每日经济新闻
Oct 20, 2023

海通国际10月20日发布研报称,给予荣昌生物(688331.SH,最新价:58.78元)优于大市评级,目标价格为79.98元。评级理由主要包括:1)得益于核心产品销量增加,公司上半年营收同比增长20.6%;2)商业化建设、医院准入持续推进,核心产品通过2023年医保国谈初步形式审查;3)泰它西普适应症持续拓展,第二个适应症申报上市;4)维迪西妥单抗适应症不断拓展;5)依托抗体和融合蛋白平台、ADC...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10